



REPLACED BY  
PAT 341457

## CLAIMS

1. Compounds having affinity to and/or selectivity for P-selectin, represented by the  
 5 following formula Ia:



and their stereo-isomers, represented by the following formula Ib:



10 wherein:

X is an optional group, which represents -O-, -OCH<sub>2</sub>-, -S-, -SCH<sub>2</sub>-, -NH- or -NHCH<sub>2</sub>-;

R<sup>1</sup> represents QR<sup>4</sup>, wherein Q represents -O-, -NH-, -NH-(C=O)-, -O-(C=O),

-NH-(C=O)-O- or -NH-(C=O)-NH-; and wherein R<sup>4</sup> represents H or any compound comprising at least one carbon atom;

15 R<sup>2</sup> is a moiety bearing at least one negative charge and

R<sup>3</sup> can be any group,

provided that if Q = -O- and R<sup>4</sup> is -H-, X is present.

2. The compounds according to claim 1, wherein X is not present or represents -O-.

20

3. The compounds according to any one of the preceding claims, wherein Q represents -NH-(C=O)-.

4. The compounds according to any one of the preceding claims, wherein R<sup>2</sup> is or comprises a phosphate group.

5. The compounds according to any one of the preceding claims, wherein R<sup>3</sup> represents OH or YR<sup>5</sup>, wherein Y is -O-, -CH<sub>2</sub>- or -NH- and R<sup>5</sup> comprises at least one carbon atom.

6. The compounds according to any one of the preceding claims, wherein R<sup>4</sup> comprises H, an alkyl moiety, an aromatic moiety or a group comprising an electron withdrawing moiety.

10 7. The compounds according to claim 6, wherein R<sup>4</sup> is a phenyl or a naphthalene group.

8. The compounds according to any one of the preceding claims, wherein R<sup>3</sup> comprises an anchor moiety capable of anchoring the compound to a colloidal or microparticulate drug carrier.

15 9. The compounds according to claim 8, wherein the anchor moiety is a peptide or peptidomimetic moiety having affinity to P-selectin.

10. The compounds according to any one of claims 1-7 as a diagnostic agent or a  
20 medicament.

11. The compounds according to any one of claims 1-7 as an antagonist for P-selectin.

12. Use of the compounds according to any one of claims 1-7 in the manufacture of a  
25 medicament for the diagnosis, prevention or inhibition of a disease or condition involving the activation or overexpression of P-selectin.

13. Use of the compounds according to any one of claims 1-7 as a targeting agent to deliver a pharmaceutically active compound to a cell or to tissue expressing P-selectin.

30 14. Pharmaceutical composition, comprising in a pharmaceutically acceptable carrier a compound according to any one of claims 1-7, or a derivative, salt, conjugate, solvate, or multimer thereof.

15. A method for determining whether a compound is capable of binding to P-selectin or a functional equivalent of P-selectin, comprising contacting and incubating the compound to be tested and a predetermined amount of a compound according to any one of claims 1-7 with a predetermined amount of P-selectin or said functional equivalent of P-selectin and  
5 subsequently determining the amount of compound according to any one of claims 1-7.